Giresun Training and Research Hospital, Department of Endocrinology and Metabolism - Giresun, Turkey.
İstinye University, Faculty of Health Sciences, Yıldızlı Medical Park Hospital, Department of Endocrinology and Metabolism - Istanbul, Turkey.
Rev Assoc Med Bras (1992). 2023 Jul 17;69(7):e20230174. doi: 10.1590/1806-9282.20230174. eCollection 2023.
The objective of this study was to examine the effects of orlistat use on metabolic control and weight loss in diabetic and nondiabetic patients.
A total of 119 patients with body mass index≥40 kg/m2 and receiving orlistat therapy, who applied to the Endocrinology polyclinic between January 2016 and October 2019, were included. The patients' weight changes and biochemical values (i.e., fasting glucose, HbA1c, ALT, creatinine, and lipid parameters) were evaluated at the drug beginning and the last polyclinic control. The patients were divided into groups, whether they had diabetes or used metformin, and compared.
The mean age of the 119 patients in the study was 45.3±11.5 years. A total of 94.1% of the patients were females and 5.9% were males. A total of 38.7% of the patients had diabetes and 29.4% had prediabetes. When the patients were compared to whether they had diabetes or used metformin, there was a statistically significant difference between the groups according to weight loss. The mean weight change of patients without diabetes and receiving metformin and orlistat was statistically significantly higher than that of patients with diabetes and receiving metformin and orlistat.
It was determined that the weight loss effect of orlistat in obesity was seen in all groups, but this effect decreased in the diabetic group.
本研究旨在探讨奥利司他对糖尿病和非糖尿病患者代谢控制和体重减轻的影响。
共纳入 2016 年 1 月至 2019 年 10 月期间在内分泌科就诊、体重指数（BMI）≥40kg/m2 并接受奥利司他治疗的 119 例患者。在开始用药和最后一次就诊时评估患者的体重变化和生化值（即空腹血糖、HbA1c、ALT、肌酐和血脂参数）。将患者分为有糖尿病或使用二甲双胍的组，并进行比较。
研究中 119 例患者的平均年龄为 45.3±11.5 岁。94.1%的患者为女性，5.9%为男性。38.7%的患者患有糖尿病，29.4%患有糖尿病前期。当比较患者是否患有糖尿病或使用二甲双胍时，根据体重减轻，两组之间存在统计学显著差异。未患有糖尿病且接受二甲双胍和奥利司他治疗的患者的平均体重变化明显高于患有糖尿病且接受二甲双胍和奥利司他治疗的患者。
确定奥利司他在肥胖患者中的减肥效果在所有组中均可见，但在糖尿病组中效果降低。
